- F&P Healthcare maintains its forecast for full-year net income between NZ$390 million and NZ$440 million, with an estimate of NZ$430.2 million.
- The company projects operating revenue between NZ$2.15 billion and NZ$2.25 billion, estimating NZ$2.24 billion.
- First-half revenue is expected to be approximately NZ$1.075 billion, with a net profit after tax of around NZ$200 million.
- This represents a 13% growth in operating revenue and a 31% growth in net profit after tax compared to the first half of the previous financial year.
- Last year’s first half saw strong performance, with a 17% revenue growth in constant currency across Homecare and Hospital product groups.
- The financial year outlook considers an estimated 75-basis point impact from US tariffs on hospital products sourced from New Zealand.
- Director Pip Greenwood plans to retire from the board effective September 1 and has joined the Australian board of Westpac Banking Corporation.
- The company will soon start the process of appointing a new director.
- Analyst ratings for the company include 5 buys, 8 holds, and 4 sells.
“`
A look at Fisher & Paykel Healthcare Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Fisher & Paykel Healthcare Corp, a company specializing in heated humidification products for respiratory care and sleep apnea treatment, is expected to have a promising long-term outlook based on the Smartkarma Smart Scores analysis. With a Growth score of 4 and a Resilience score of 5, the company shows strong potential for expansion and stability in the face of challenges. Additionally, its Momentum score of 4 indicates positive market trends that may support continued growth.
While Fisher & Paykel Healthcare Corp receives moderate scores in Value and Dividend factors (2 each), its overall outlook remains optimistic, buoyed by solid ratings in Growth, Resilience, and Momentum. As a leader in designing and manufacturing healthcare products, with a focus on respiratory and neonatal care solutions, the company’s strategic positioning and product offerings may contribute to its continued success in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
